BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ossorio PN, Zhou Y. FMT and Microbial Medical Products: Generating High-Quality Evidence through Good Governance. J Law Med Ethics 2019;47:505-23. [DOI: 10.1177/1073110519897727] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Khoruts A, Hoffmann DE, Palumbo FB. The Impact of Regulatory Policies on the Future of Fecal Microbiota Transplantation. J Law Med Ethics 2019;47:482-504. [PMID: 31957587 DOI: 10.1177/1073110519897726] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
2 Hoffmann DE. Introduction: The Promise and Challenges of Microbiome-Based Therapies. J Law Med Ethics 2019;47:476-81. [PMID: 31957585 DOI: 10.1177/1073110519897725] [Reference Citation Analysis]
3 Scheeler A. Where Stool is a Drug: International Approaches to Regulating the use of Fecal Microbiota for Transplantation. J Law Med Ethics 2019;47:524-40. [PMID: 31957572 DOI: 10.1177/1073110519897729] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
4 Donovan SM. Evolution of the gut microbiome in infancy within an ecological context. Curr Opin Clin Nutr Metab Care 2020;23:223-7. [PMID: 32167987 DOI: 10.1097/MCO.0000000000000650] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]